167 related articles for article (PubMed ID: 28484093)
21. MicroRNA-302 represses epithelial-mesenchymal transition and cisplatin resistance by regulating ATAD2 in ovarian carcinoma.
Ge T; Liu T; Guo L; Chen Z; Lou G
Exp Cell Res; 2020 Nov; 396(1):112241. PubMed ID: 32835657
[TBL] [Abstract][Full Text] [Related]
22. A novel trans-platinum coordination complex possessing in vitro and in vivo antitumor activity.
Kelland LR; Barnard CF; Mellish KJ; Jones M; Goddard PM; Valenti M; Bryant A; Murrer BA; Harrap KR
Cancer Res; 1994 Nov; 54(21):5618-22. PubMed ID: 7923207
[TBL] [Abstract][Full Text] [Related]
23. Targeted Drug Delivery and Image-Guided Therapy of Heterogeneous Ovarian Cancer Using HER2-Targeted Theranostic Nanoparticles.
Satpathy M; Wang L; Zielinski RJ; Qian W; Wang YA; Mohs AM; Kairdolf BA; Ji X; Capala J; Lipowska M; Nie S; Mao H; Yang L
Theranostics; 2019; 9(3):778-795. PubMed ID: 30809308
[TBL] [Abstract][Full Text] [Related]
24. Sequential combination of cisplatin with eugenol targets ovarian cancer stem cells through the Notch-Hes1 signalling pathway.
Islam SS; Aboussekhra A
J Exp Clin Cancer Res; 2019 Aug; 38(1):382. PubMed ID: 31470883
[TBL] [Abstract][Full Text] [Related]
25. A stabilized retro-inverso peptide ligand of transferrin receptor for enhanced liposome-based hepatocellular carcinoma-targeted drug delivery.
Tang J; Wang Q; Yu Q; Qiu Y; Mei L; Wan D; Wang X; Li M; He Q
Acta Biomater; 2019 Jan; 83():379-389. PubMed ID: 30395963
[TBL] [Abstract][Full Text] [Related]
26. Synergistic targeted delivery of payload into tumor cells by dual-ligand liposomes co-modified with cholesterol anchored transferrin and TAT.
Tang J; Zhang L; Liu Y; Zhang Q; Qin Y; Yin Y; Yuan W; Yang Y; Xie Y; Zhang Z; He Q
Int J Pharm; 2013 Sep; 454(1):31-40. PubMed ID: 23850793
[TBL] [Abstract][Full Text] [Related]
27. MCT1 promotes the cisplatin-resistance by antagonizing Fas in epithelial ovarian cancer.
Yan C; Yang F; Zhou C; Chen X; Han X; Liu X; Ma H; Zheng W
Int J Clin Exp Pathol; 2015; 8(3):2710-8. PubMed ID: 26045776
[TBL] [Abstract][Full Text] [Related]
28. Rapamycin enhanced the antitumor efficacy of oxaliplatin in cisplatin-resistant ovarian cancer cells A2780cis both in vitro and in vivo.
Liu J; Zhang L; Zhang X; Xing X
J Chemother; 2015; 27(6):358-64. PubMed ID: 25976336
[TBL] [Abstract][Full Text] [Related]
29. Fabrication, in-silico, in-vitro, and in-vivo characterization of transferrin-targeted micelles containing cisplatin and gadolinium for improved theranostic applications in lung cancer therapy.
Yadav B; Chauhan M; Sonali ; Dinkar R; Shekhar S; Singh RP
Eur J Pharm Biopharm; 2023 Dec; 193():44-57. PubMed ID: 37866420
[TBL] [Abstract][Full Text] [Related]
30. Inhibition of the IGF signaling pathway reverses cisplatin resistance in ovarian cancer cells.
Du J; Shi HR; Ren F; Wang JL; Wu QH; Li X; Zhang RT
BMC Cancer; 2017 Dec; 17(1):851. PubMed ID: 29241458
[TBL] [Abstract][Full Text] [Related]
31. Copper sulfide nanoparticle-based localized drug delivery system as an effective cancer synergistic treatment and theranostic platform.
Hou L; Shan X; Hao L; Feng Q; Zhang Z
Acta Biomater; 2017 May; 54():307-320. PubMed ID: 28274767
[TBL] [Abstract][Full Text] [Related]
32. The Impact of the Low Molecular Weight Heparin Tinzaparin on the Sensitization of Cisplatin-Resistant Ovarian Cancers-Preclinical In Vivo Evaluation in Xenograft Tumor Models.
Mueller T; Pfankuchen DB; Wantoch von Rekowski K; Schlesinger M; Reipsch F; Bendas G
Molecules; 2017 May; 22(5):. PubMed ID: 28467373
[TBL] [Abstract][Full Text] [Related]
33. Transferrin serves as a mediator to deliver organometallic ruthenium(II) anticancer complexes into cells.
Guo W; Zheng W; Luo Q; Li X; Zhao Y; Xiong S; Wang F
Inorg Chem; 2013 May; 52(9):5328-38. PubMed ID: 23586415
[TBL] [Abstract][Full Text] [Related]
34. The cisplatin-induced lncRNA PANDAR dictates the chemoresistance of ovarian cancer via regulating SFRS2-mediated p53 phosphorylation.
Wang H; Fang L; Jiang J; Kuang Y; Wang B; Shang X; Han P; Li Y; Liu M; Zhang Z; Li P
Cell Death Dis; 2018 Oct; 9(11):1103. PubMed ID: 30375398
[TBL] [Abstract][Full Text] [Related]
35. Increased apoptosis in cancer cells in vitro and in vivo by ceramides in transferrin-modified liposomes.
Koshkaryev A; Piroyan A; Torchilin VP
Cancer Biol Ther; 2012 Jan; 13(1):50-60. PubMed ID: 22336588
[TBL] [Abstract][Full Text] [Related]
36. miR-142-5p enhances cisplatin-induced apoptosis in ovarian cancer cells by targeting multiple anti-apoptotic genes.
Li X; Chen W; Jin Y; Xue R; Su J; Mu Z; Li J; Jiang S
Biochem Pharmacol; 2019 Mar; 161():98-112. PubMed ID: 30639456
[TBL] [Abstract][Full Text] [Related]
37. Cross-reacting material 197, a heparin-binding EGF-like growth factor inhibitor, reverses the chemoresistance in human cisplatin-resistant ovarian cancer.
Tang XH; Li M; Deng S; Lu MS
Anticancer Drugs; 2014 Nov; 25(10):1201-10. PubMed ID: 25115341
[TBL] [Abstract][Full Text] [Related]
38. Vanadium(V/IV)-Transferrin Binding Disrupts the Transferrin Cycle and Reduces Vanadium Uptake and Antiproliferative Activity in Human Lung Cancer Cells.
Levina A; Lay PA
Inorg Chem; 2020 Nov; 59(22):16143-16153. PubMed ID: 32578416
[TBL] [Abstract][Full Text] [Related]
39. Differential activation of NF-κB signaling is associated with platinum and taxane resistance in MyD88 deficient epithelial ovarian cancer cells.
Gaikwad SM; Thakur B; Sakpal A; Singh RK; Ray P
Int J Biochem Cell Biol; 2015 Apr; 61():90-102. PubMed ID: 25681684
[TBL] [Abstract][Full Text] [Related]
40. A potent oncolytic adenovirus selectively blocks the STAT3 signaling pathway and potentiates cisplatin antitumor activity in ovarian cancer.
Han Z; Hong Z; Gao Q; Chen C; Hao Z; Ji T; Hu W; Yan Y; Feng J; Liao S; Wu P; Wang D; Wang S; Zhou J; Ma D
Hum Gene Ther; 2012 Jan; 23(1):32-45. PubMed ID: 21875334
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
